MediPharm Labs Corp.
LABS.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -7.76% | 15.70% | 12.83% | 3.89% | 28.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -7.76% | 15.70% | 12.83% | 3.89% | 28.18% |
| Cost of Revenue | -21.08% | 33.94% | 23.24% | -9.14% | 99.88% |
| Gross Profit | 36.09% | -21.60% | -6.85% | 34.56% | -41.23% |
| SG&A Expenses | 1.22% | -18.33% | 19.43% | -31.07% | 30.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 117.81% | -17.20% | -334.02% | 16.16% | 191.83% |
| Total Operating Expenses | -12.40% | 8.93% | 20.64% | -19.67% | 69.80% |
| Operating Income | 44.39% | 16.60% | -54.15% | 87.79% | -236.96% |
| Income Before Tax | -14.49% | 23.53% | -44.34% | 89.93% | 45.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.49% | 23.53% | -44.34% | 89.93% | 39.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.49% | 23.53% | -44.34% | 89.93% | 39.81% |
| EBIT | 44.39% | 16.60% | -54.15% | 87.79% | -236.96% |
| EBITDA | 53.42% | 15.40% | -97.04% | 99.17% | -165.78% |
| EPS Basic | -10.00% | 24.49% | -40.43% | 90.91% | 44.44% |
| Normalized Basic EPS | 44.44% | 23.33% | -51.85% | 89.47% | -200.00% |
| EPS Diluted | -10.00% | 24.49% | -40.43% | 90.91% | 44.44% |
| Normalized Diluted EPS | 44.44% | 23.33% | -51.85% | 89.47% | -200.00% |
| Average Basic Shares Outstanding | 2.40% | 2.36% | 2.61% | 2.83% | 9.01% |
| Average Diluted Shares Outstanding | 2.40% | 2.36% | 2.61% | 2.83% | 9.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |